Tiny Giant? An Underdog Makes its Mark

Novavax, a small US drug maker, is relatively unknown. But their first-ever vaccine—for COVID-19—proved as effective as big-name competitors in a UK trial.

The company is preparing to file for authorization in the US and India. South Korea is already aiming for local production in June.

Novavax—which believes its vaccine can be easily modified to address emerging variants—pledged 100 million doses to the US and expects to contribute to WHO’s COVAX initiative.

As competitors like Johnson & Johnson face bumps in the road, “I think Novavax is going to be a reasonably significant player,” said Georgetown University’s Lawrence Gostin. 

POLITICO

Secondary Topic
Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top